Advisors

Gordon Keller, Ph.D

Dr. Gordon Keller earned his PhD in Immunology at the University of Alberta in 1979 and completed a Post Doctoral Fellowship at the Ontario Cancer Institute in Toronto in 1983.  Following post doctoral studies, he became a Member of the Basel Institute for Immunology in Switzerland where he worked for five years, then moved to Vienna Austria where he accepted a post of Visiting Scientist at the Research Institute of Molecular Pathology.  In 1990, Keller moved to the United States, working initially at the National Jewish Centre for Immunology and Respiratory Medicine in Denver Colorado and from 1999-2006 as a Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in New York. In 2005, he was appointed as the Director of the Black Family Stem Cell Institute within the Mt. Sinai School of Medicine. As of January 2007, Keller returned to Canada to accept the position of Director of the McEwen Centre for Regenerative Medicine at the University Health Network in Toronto.  Dr. Keller is best known for his research in lineage specific differentiation of mouse and human embryonic stem cells.

Rob Coffin, Ph.D

Robert Coffin is CEO and co-founder of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his prior research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC) that was recently approved by the FDA and is the first gene therapy product ever approved in the USA. Rob oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer under SPA before sale of BioVex to Amgen in 2011 where he became VP Global Development until 2013. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991. Subsequent to Amgen, Rob has provided general biotech advisory services in gene therapy, oncolytic viruses, oncology drug development, cell therapy, immunotherapy and vaccines including in particular to Uniqure and Universal Cells Inc.